Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 87, Issue 6, Pages 503-509Publisher
WILEY
DOI: 10.1111/j.1600-0609.2011.01685.x
Keywords
allogeneic haematopoietic stem cell transplantation; prograf; cyclosporine; rapamune; inborn error of metabolism; Epstein-Barr virus lymphoma
Categories
Funding
- Swedish Cancer Society [CAN 2008/562]
- Children's Cancer Foundation [09/093]
- Swedish Research Council [K2008-64X-05971-28-3]
- Cancer Society in Stockholm and Karolinska Institutet
Ask authors/readers for more resources
For prevention of graft-versus-host disease (GVHD), treatment of 24 haematopoietic stem cell transplantation (HSCT) patients with sirolimus and tacrolimus was compared to treatment of matched controls with cyclosporine-based regimens. The patients mainly had non-malignant disorders. Two-thirds of the donors were unrelated, and bone marrow was the most common source of stem cells. Rejection occurred in four patients in the sirolimus group and three in the control group. Donor chimerism for CD3, CD19 and CD33 was similar in the two groups. The cumulative incidence of grade II acute GVHD was 22% in the sirolimus patients and 17% in the controls (P = 0.78). No patients developed acute GVHD of grades IIIIV. The cumulative incidence of chronic GVHD was 25% and 37% in the two groups, respectively (P = 0.40). Two patients in the sirolimus group developed EpsteinBarr virus lymphoma, and none in the controls. Side effects and toxicity were similar in the two groups. There was no transplant-related mortality at 5 yr in the sirolimus group, as opposed to 8% in the controls (P = 0.47). Survival at 5 yr was 95% and 92%. Thus, sirolimus combined with tacrolimus is a promising immunosuppressive regimen in HSCT, also for non-malignancies, and its efficacy should be confirmed in prospective clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available